CN Mobile Logo

Search form


Chemo/Radiotherapy Sequence May Not Affect Breast Cancer Outcomes

Chemo/Radiotherapy Sequence May Not Affect Breast Cancer Outcomes

SAN FRANCISCO—Time to failure, time to distant metastasis, and time
to death in patients with early-stage breast cancer are not influenced by the
order in which chemotherapy and radiotherapy are initiated, according to
updated results of a study presented at the 43rd Annual Meeting of the American
Society for Therapeutic Radiology and Oncology (ASTRO plenary 4). These latest
long-term results are in contrast to earlier findings from the study.

"The initial results of the study were published in 1996 with 58 months
of follow-up," said Jennifer Bellon, MD, an instructor at Brigham and
Women’s Hospital, Boston. At that time, she said, patients randomized to the
radiotherapy-first arm had a lower 5-year crude rate of local recurrence,
whereas the patients randomized to the chemotherapy-first arm had a lower rate
of distant and/or regional metastasis.

"Adjuvant chemotherapy preceding radiation has become common practice
in women with early-stage breast cancer who undergo breast-conserving
surgery," she said.

The new 10-year findings show no significant difference in freedom from any
recurrence, freedom from distant metastasis, or overall survival between the
two arms, Dr. Bellon said, based on a median follow-up of 135 months. She added that the power to detect differences, which is based on
number of failures, is still low, and that additional results from this and
other trials are necessary to determine the optimal therapy sequence.

The Boston-based study followed 244 women with stage I/II carcinoma of the
breast treated with breast-conserving surgery. They were randomized to receive,
after surgery, 12 weeks of chemotherapy either before radiotherapy (CT-first
arm) or following radiotherapy (RT-first arm).

The two arms were matched for tumor and patient characteristics, including
age, T stage, margins, and nodal status (for details, see N Engl J Med
334:1356-1361, 1996).

Chemotherapy consisted of a six-drug regimen repeated every 3 weeks for four
cycles. Tamoxifen (Nolvadex) was given following completion of all chemotherapy
and radiotherapy to 11 patients in the CT-first arm and 7 patients in the
RT-first arm.


By clicking Accept, you agree to become a member of the UBM Medica Community.